Chimeric antigen receptor T cell (CAR-T) therapy is approved for treatment of
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Here we evaluate whether …

ABSTRACT CD19-targeted chimeric antigen receptor (CAR) T cells have shown excellent
activity against relapsed and refractory (R/R) diffuse large B cell lymphoma (DLBCL). CAR T …

Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …

Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …

Autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T‐
cell therapy (CART) are salvage therapies that are utilised for treatment of relapsed or …

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …

Background We aimed to compare the efficacy of chimeric antigen receptor T (CAR-T) cell
therapy with that of autologous stem cell transplantation (auto-HSCT) in relapsed/refractory …

Anti-CD19 chimeric antigen receptor (CAR) T cells represent the first approved third-line
therapy associated with long-term remissions in patients with refractory/relapsed (R/R) …

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's
lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years …

The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …